Polymorphism inANRILis associated with relapse in patients with multiple myeloma after autologous stem cell transplant
Autor: | Zachary VanGundy, Junan Li, Douglas W. Sborov, Misty Lamprecht, Mitch A. Phelps, Craig C. Hofmeister, Yu Kyoung Cho, Ming Poi, Flavia Pichiorri |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Melphalan Cancer Research medicine.medical_treatment Single-nucleotide polymorphism Hematopoietic stem cell transplantation Biology medicine.disease Peripheral blood mononuclear cell 03 medical and health sciences 030104 developmental biology 0302 clinical medicine p14arf 030220 oncology & carcinogenesis Monoclonal Cancer research medicine Stem cell Molecular Biology Multiple myeloma medicine.drug |
Zdroj: | Molecular Carcinogenesis. 56:1722-1732 |
ISSN: | 0899-1987 |
DOI: | 10.1002/mc.22626 |
Popis: | Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells and overproduction of monoclonal immunoglobins. Treatment with melphalan is currently standard of care for younger and fit patients when followed by hematopoietic stem cell transplantation (HSCT), and in transplant ineligible patients when used in combination regimens. It has been previously shown that changes in the p53 pathway are associated with melphalan efficacy, but the regulatory role of the p14ARF-MDM2-p53 axis has yet to be fully explored. Recently, a non-coding RNA, ANRIL (antisense non-coding RNA in the INK4-ARF locus) has been shown to negatively regulate the transcription of the entire INK4-ARF locus and simultaneously modulate the p53 and pRb pathways. Moreover, some single nucleotide polymorphisms (SNPs) in ANRIL have previously been associated with susceptibility to several malignancies. Here we investigated select ANRIL SNPs in DNA from patient-derived peripheral blood mononuclear cells obtained from 108 MM patients treated with high-dose melphalan followed by HSCT. Our results show that the rs2151280 (CaT) SNP in ANRIL was associated with worse progression-free survival (TC/CC vs TT: HR = 0.53, 95%CI, [0.26, 1.07], P = 0.07; adjusted HR = 0.39, 95%CI, [0.18, 0.84], P = 0.016), and the TT variant had higher ANRIL expression and lower p15, p14ARF, and p16 expression compared to the TC/CC variants. Our results indicate that ANRIL may be involved in melphalan-mediated apoptosis via down-regulating p14ARF and subsequent p53, and that the rs2151280 polymorphism may be a potential prognostic biomarker for relapse in melphalan-treated MM patients. |
Databáze: | OpenAIRE |
Externí odkaz: |